Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
European Journal of Nuclear Medicine and Molecular Imaging
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 3/2017

14.11.2016 | Review Article

Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies

verfasst von: Christopher G. England, Lixin Rui, Weibo Cai

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Lymphoma is a complex disease that arises from cells of the immune system with an intricate pathology. While lymphoma may be classified as Hodgkin or non-Hodgkin, each type of tumor is genetically and phenotypically different and highly invasive tissue biopsies are the only method to investigate these differences. Noninvasive imaging strategies, such as immunoPET, can provide a vital insight into disease staging, monitoring treatment response in patients, and dose planning in radioimmunotherapy. ImmunoPET imaging with radiolabeled antibody-based tracers may also assist physicians in optimizing treatment strategies and enhancing patient stratification. Currently, there are two common biomarkers for molecular imaging of lymphoma, CD20 and CD30, both of which have been considered for investigation in preclinical imaging studies. In this review, we examine the current status of both preclinical and clinical imaging of lymphoma using radiolabeled antibodies. Additionally, we briefly investigate the role of radiolabeled antibodies in lymphoma therapy. As radiolabeled antibodies play critical roles in both imaging and therapy of lymphoma, the development of novel antibodies and the discovery of new biomarkers may greatly affect lymphoma imaging and therapy in the future.
Literatur
1.
2.
Engels EA. Infectious agents as causes of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 2007;16(3):401–404.PubMedCrossRef
3.
4.
Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–5032.PubMedPubMedCentralCrossRef
5.
Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.PubMedCrossRef
6.
Swerdlow SH. Lymphoma classification and the tools of our trade: an introduction to the 2012 USCAP Long Course. Mod Pathol. 2013;26 Suppl 1:S1–S14.PubMedCrossRef
7.
Turner JJ, Hughes AM, Kricker A, et al. WHO non-Hodgkin’s lymphoma classification by criterion-based report review followed by targeted pathology review: an effective strategy for epidemiology studies. Cancer Epidemiol Biomarkers Prev. 2005;14(9):2213–2219.PubMedCrossRef
8.
9.
Dotan E, Aggarwal C, Smith MR. Impact of rituximab (Rituxan) on the treatment of B-cell non-Hodgkin’s lymphoma. Pharm Ther. 2010;35(3):148–157.
10.
Meng F, Zhong D, Zhang L, Shao Y, Ma Q. Efficacy and safety of rituximab combined with chemotherapy in the treatment of diffuse large B-cell lymphoma: a meta-analysis. Int J Clin Exp Med. 2015;8(10):17515–17522.PubMedPubMedCentral
11.
Rukstalis DB. Treatment options after failure of radiation therapy – a review. Rev Urol. 2002;4 Suppl 2:S12–S17.PubMedPubMedCentral
12.
Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016;13(5):273–90.PubMedCrossRef
13.
14.
Kharfan-Dabaja MA, Hamadani M, Sibai H, Savani BN. Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all. Bone Marrow Transplant. 2014;49(5):599–606.PubMedCrossRef
15.
Toma P, Granata C, Rossi A, Garaventa A. Multimodality imaging of Hodgkin disease and non-Hodgkin lymphomas in children. Radiographics. 2007;27(5):1335–1354.PubMedCrossRef
16.
Gobbi PG, Ferreri AJ, Ponzoni M, Levis A. Hodgkin lymphoma. Crit Rev Oncol Hematol. 2013;85(2):216–237.PubMedCrossRef
17.
Luminari S, Bellei M, Biasoli I, Federico M. Follicular lymphoma – treatment and prognostic factors. Rev Bras Hematol Hemoter. 2012;34(1):54–9.PubMedPubMedCentralCrossRef
18.
Ferrer R. Lymphadenopathy: differential diagnosis and evaluation. Am Fam Physician. 1998;58(6):1313–1320.PubMed
19.
Jung W, Trumper L. Differential diagnosis and diagnostic strategies of lymphadenopathy. Internist (Berl). 2008;49(3):305–318.CrossRef
20.
Wang H, Qiu LN, Wu M, et al. Secondary B-cell lymphoma diagnosed by fine-needle aspiration cytology and flow cytometry following penile carcinoma: a case report. Oncol Lett. 2016;11(4):2449–2452.PubMedPubMedCentral
21.
Demurtas A, Accinelli G, Pacchioni D, et al. Utility of flow cytometry immunophenotyping in fine-needle aspirate cytologic diagnosis of non-Hodgkin lymphoma: a series of 252 cases and review of the literature. Appl Immunohistochem Mol Morphol. 2010;18(4):311–22.PubMedCrossRef
22.
23.
Zeppa P, Marino G, Troncone G, et al. Fine-needle cytology and flow cytometry immunophenotyping and subclassification of non-Hodgkin lymphoma: a critical review of 307 cases with technical suggestions. Cancer. 2004;102(1):55–65.PubMedCrossRef
24.
Maecker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping for the human immunology project. Nat Rev Immunol. 2012;12(3):191–200.PubMedPubMedCentral
25.
Reichard KK, Robinett S. Detection of genetic translocations in lymphoma using fluorescence in situ hybridization. Methods Mol Biol. 2013;999:189–202.PubMedCrossRef
26.
Friedberg JW, Chengazi V. PET scans in the staging of lymphoma: current status. Oncologist. 2003;8(5):438–447.PubMedCrossRef
27.
Wu AM, Olafsen T. Antibodies for molecular imaging of cancer. Cancer J. 2008;14(3):191–197.PubMedCrossRef
28.
Abdel Gawad EA, Abu Samra MF, Talat AM. The utility of multi-detector CT in detection and characterization of mesenteric lymphadenopathy with histopathological confirmation. Egypt J Radiol Nucl Med. 2016;47(3):757–764.CrossRef
29.
Kwee TC, Kwee RM, Nievelstein RA. Imaging in staging of malignant lymphoma: a systematic review. Blood. 2008;111(2):504–516.PubMedCrossRef
30.
Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32(27):3048–3058.PubMedPubMedCentralCrossRef
31.
Kwee TC, Takahara T, Vermoolen MA, Bierings MB, Mali WP, Nievelstein RA. Whole-body diffusion-weighted imaging for staging malignant lymphoma in children. Pediatr Radiol. 2010;40(10):1592–1602.PubMedPubMedCentralCrossRef
32.
Kwee TC, van Ufford HM, Beek FJ, et al. Whole-body MRI, including diffusion-weighted imaging, for the initial staging of malignant lymphoma: comparison to computed tomography. Invest Radiol. 2009;44(10):683–690.PubMedCrossRef
33.
Edwards CL, Hayes RL. Tumor scanning with 67Ga citrate. J Nucl Med. 1969;10(2):103–105.PubMed
34.
35.
36.
Adler S, Parthasarathy KL, Bakshi SP, Stutzman L. Gallium-67-citrate scanning for the localization and staging of lymphomas. J Nucl Med. 1975;16(4):255–260.PubMed
37.
van Leeuwen-Stok AE, Schuurhuis GJ, Drager AM, Visser-Platier AW, Teule GJ, Huijgens PC. Effect of modulation of the transferrin receptor on gallium-67 uptake and cytotoxicity in lymphoma cell lines. Br J Cancer. 1996;74(4):619–624.PubMedPubMedCentralCrossRef
38.
Horn NL, Ray GR, Kriss JP. Gallium-67 citrate scanning in Hodgkin’s disease and non-Hodgkin’s lymphoma. Cancer. 1976;37(1):250–257.PubMedCrossRef
39.
Cwikla JB, Buscombe JR, Thakrar DS, Irwin AG, Hilson AJ. 67Ga SPECT in detection of infection and inflammation. Nucl Med Rev Cent East Eur. 1999;2(2):69–73.PubMed
40.
Kostakoglu L, Yeh SD, Portlock C, et al. Validation of gallium-67-citrate single-photon emission computed tomography in biopsy-confirmed residual Hodgkin’s disease in the mediastinum. J Nucl Med. 1992;33(3):345–350.PubMed
41.
Fuertes MJ, Estorch CM, Camacho MV, et al. SPECT-CT 67Ga studies in lymphoma disease. Contribution to staging and follow-up. Rev Esp Med Nucl. 2006;25(4):242–249.CrossRef
42.
Iagaru A, Goris ML, Gambhir SS. Perspectives of molecular imaging and radioimmunotherapy in lymphoma. Radiol Clin N Am. 2008;46(2):243–252.PubMedCrossRef
43.
Paul R. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J Nucl Med. 1987;28(3):288–292.PubMed
44.
Hoh CK, Glaspy J, Rosen P, et al. Whole-body FDG-PET imaging for staging of Hodgkin’s disease and lymphoma. J Nucl Med. 1997;38(3):343–348.PubMed
45.
Kostakoglu L, Leonard JP, Kuji I, Coleman M, Vallabhajosula S, Goldsmith SJ. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer. 2002;94(4):879–88.PubMedCrossRef
46.
Bar-Shalom R, Yefremov N, Haim N, et al. Camera-based FDG PET and 67Ga SPECT in evaluation of lymphoma: comparative study. Radiology. 2003;227(2):353–60.PubMedCrossRef
47.
Yang CC, Sun SS, Lin CC, Kao CH, Lee CC. Comparison of technetium-99m tetrofosmin and gallium-67 citrate scintigraphy for detecting malignant lymphoma. Anticancer Res. 2001;21(5):3695–3698.PubMed
48.
Shen YY, Kao A, Yen RF. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma. Oncol Rep. 2002;9(2):321–325.PubMed
49.
Talbot JN, Haioun C, Rain JD, et al. [18F]-FDG positron imaging in clinical management of lymphoma patients. Crit Rev Oncol Hematol. 2001;38(3):193–221.PubMedCrossRef
50.
Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med. 2002;43(8):1018–1027.PubMed
51.
Mikhaeel NG, Hutchings M, Fields PA, O’Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol. 2005;16(9):1514–1523.PubMedCrossRef
52.
Langer A. A systematic review of PET and PET/CT in oncology: a way to personalize cancer treatment in a cost-effective manner? BMC Health Serv Res. 2010;10(1):283.PubMedPubMedCentralCrossRef
53.
Girinsky T, Auperin A, Ribrag V, et al. Role of FDG-PET in the implementation of involved-node radiation therapy for Hodgkin lymphoma patients. Int J Radiat Oncol Biol Phys. 2014;89(5):1047–1052.PubMedCrossRef
54.
55.
Haldorsen IS, Espeland A, Larsson EM. Central nervous system lymphoma: characteristic findings on traditional and advanced imaging. Am J Neuroradiol. 2011;32(6):984–992.PubMedCrossRef
56.
Carter BW, Wu CC, Khorashadi L, et al. Multimodality imaging of cardiothoracic lymphoma. Eur J Radiol. 2014;83(8):1470–1482.PubMedCrossRef
57.
Stephane V, Samuel B, Vincent D, et al. Comparison of PET-CT and magnetic resonance diffusion weighted imaging with body suppression (DWIBS) for initial staging of malignant lymphomas. Eur J Radiol. 2013;82(11):2011–7.PubMedCrossRef
58.
Akay S, Kocaoglu M, Emer O, Battal B, Arslan N. Diagnostic accuracy of whole-body diffusion-weighted magnetic resonance imaging with 3.0 T in detection of primary and metastatic neoplasms. J Med Imaging Radiat Oncol. 2013;57(3):274–282.PubMedCrossRef
59.
Palomero T, Ferrando AA. Genomic tools for dissecting oncogenic transcriptional networks in human leukemia. Leukemia. 2009;23(7):1236–1242.PubMedCrossRef
60.
Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009;114(11):2273–2279.PubMedPubMedCentralCrossRef
61.
Li S, Lin P, Young KH, Kanagal-Shamanna R, Yin CC, Medeiros LJ. MYC/BCL2 double-hit high-grade B-cell lymphoma. Adv Anat Pathol. 2013;20(5):315–326.PubMedCrossRef
62.
Battey J, Moulding C, Taub R, et al. The human c-myc oncogene: structural consequences of translocation into the IgH locus in Burkitt lymphoma. Cell. 1983;34(3):779–787.PubMedCrossRef
63.
Ott G, Rosenwald A, Campo E. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Blood. 2013;122(24):3884–3491.
64.
Taub R, Kirsch I, Morton C, et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci U S A. 1982;79(24):7837–7841.PubMedPubMedCentralCrossRef
65.
Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, Adams JM. The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med. 1988;167(2):353–371.PubMedCrossRef
66.
Sheppard RD, Samant SA, Rosenberg M, Silver LM, Cole MD. Transgenic N-myc mouse model for indolent B cell lymphoma: tumor characterization and analysis of genetic alterations in spontaneous and retrovirally accelerated tumors. Oncogene. 1998;17(16):2073–2085.PubMedCrossRef
67.
68.
69.
Wang CG, Tai YH, Lisanti MP, Liao DJ. c-Myc induction of programmed cell death may contribute to carcinogenesis a perspective inspired by several concepts of chemical carcinogenesis. Cancer Biol Ther. 2011;11(7):615–626.PubMedPubMedCentralCrossRef
70.
Kirkin V, Joos S, Zornig M. The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta. 2004;1644(2-3):229–249.PubMedCrossRef
71.
Eischen CM, Woo D, Roussel MF, Cleveland JL. Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis. Mol Cell Biol. 2001;21(15):5063–5070.PubMedPubMedCentralCrossRef
72.
Donnou S, Galand C, Touitou V, Sautes-Fridman C, Fabry Z, Fisson S. Murine models of B-cell lymphomas: promising tools for designing cancer therapies. Adv Hematol. 2012;2012:701–704.CrossRef
73.
Kasama Y, Sekiguchi S, Saito M, et al. Persistent expression of the full genome of hepatitis C virus in B cells induces spontaneous development of B-cell lymphomas in vivo. Blood. 2010;116(23):4926–4933.PubMedPubMedCentralCrossRef
74.
Jinadasa R, Balmus G, Gerwitz L, Roden J, Weiss R, Duhamel G. Derivation of thymic lymphoma T-cell lines from Atm(-/-) and p53(-/-) mice. J Vis Exp. 2011;50, 2598.
75.
Dranoff G. Experimental mouse tumour models: what can be learnt about human cancer immunology? Nat Rev Immunol. 2012;12(1):61–66.
76.
Klein AS, Plata F, Jackson MJ, Shin S. Cellular tumorigenicity in nude mice. Role of susceptibility to natural killer cells. Exp Cell Biol. 1979;47(6):430–445.PubMed
77.
Hanna N. The role of natural killer cells in the control of tumor growth and metastasis. Biochim Biophys Acta. 1985;780(3):213–226.PubMed
78.
O’Connor OA, Toner LE, Vrhovac R, Budak-Alpdogan T, Smith EA, Bergman P. Comparative animal models for the study of lymphohematopoietic tumors: strengths and limitations of present approaches. Leuk Lymphoma. 2005;46(7):973–992.PubMedCrossRef
79.
Hunter RF, Roth PA, Huang AT. Cutaneous T cell lymphoma. Lymphocyte phenotype analysis after anti-thymocyte globulin therapy. Am J Med. 1985;79(5):653–658.PubMedCrossRef
80.
Imada K. Immunodeficient mouse models of lymphoid tumors. Int J Hematol. 2003;77(4):336–341.PubMedCrossRef
81.
Volpe R, Kasuga Y, Akasu F, et al. The use of the severe combined immunodeficient mouse and the athymic "nude" mouse as models for the study of human autoimmune thyroid disease. Clin Immunol Immunopathol. 1993;67(2):93–99.PubMedCrossRef
82.
Shimada K, Shimada S, Sugimoto K, et al. Development and analysis of patient-derived xenograft mouse models in intravascular large B-cell lymphoma. Leukemia. 2016;30(7):1568–1579.PubMedCrossRef
83.
84.
Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol. 2007;7(2):118–130.PubMedCrossRef
85.
Ali N, Flutter B, Sanchez Rodriguez R, et al. Xenogeneic graft-versus-host-disease in NOD-scid IL-2Rgammanull mice display a T-effector memory phenotype. PLoS One. 2012;7(8), e44219.PubMedPubMedCentralCrossRef
86.
Covassin L, Jangalwe S, Jouvet N, et al. Human immune system development and survival of non-obese diabetic (NOD)-scid IL2rgamma(null) (NSG) mice engrafted with human thymus and autologous haematopoietic stem cells. Clin Exp Immunol. 2013;174(3):372–388.PubMedPubMedCentralCrossRef
87.
Keating GM. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs. 2010;70(11):1445–1476.PubMedCrossRef
88.
Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs. 2003;63(8):803–843.PubMedCrossRef
89.
Barakzai MA, Pervez S. CD20 positivity in classical Hodgkin’s lymphoma: diagnostic challenge or targeting opportunity. Indian J Pathol Microbiol. 2009;52(1):6–9.PubMedCrossRef
90.
Avivi I, Stroopinsky D, Katz T. Anti-CD20 monoclonal antibodies: beyond B-cells. Blood Rev. 2013;27(5):217–223.PubMedCrossRef
91.
Grillo-Lopez AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol. 1999;26(5 Suppl 14):66–73.PubMed
92.
Grillo-Lopez AJ, White CA, Dallaire BK, et al. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol. 2000;1(1):1–9.PubMedCrossRef
93.
Natarajan A, Habte F, Gambhir SS. Development of a novel long-lived immunoPET tracer for monitoring lymphoma therapy in a humanized transgenic mouse model. Bioconjug Chem. 2012;23(6):1221–1229.PubMedPubMedCentralCrossRef
94.
95.
Natarajan A, Gambhir SS. Radiation dosimetry study of [(89)Zr]rituximab tracer for clinical translation of B cell NHL Imaging using positron emission tomography. Mol Imaging Biol. 2015;17(4):539–547.PubMedPubMedCentralCrossRef
96.
Natarajan A, Habte F, Liu H, et al. Evaluation of 89Zr-rituximab tracer by Cerenkov luminescence imaging and correlation with PET in a humanized transgenic mouse model to image NHL. Mol Imaging Biol. 2013;15(4):468–475.PubMedCrossRef
97.
Natarajan A, Gowrishankar G, Nielsen CH, et al. Positron emission tomography of 64Cu-DOTA-rituximab in a transgenic mouse model expressing human CD20 for clinical translation to image NHL. Mol Imaging Biol. 2012;14(5):608–616.PubMedCrossRef
98.
Fontan C, Bezombes C, Salabert AS, et al. Radiolabelling rituximab with (99m)Tc in three steps procedure. J Labelled Comp Radiopharm. 2015;58(7):274–280.PubMedCrossRef
99.
Biffi S, Garrovo C, Macor P, et al. In vivo biodistribution and lifetime analysis of Cy5.5-conjugated rituximab in mice bearing lymphoid tumor xenograft using time-domain near-infrared optical imaging. Mol Imaging. 2008;7(6):272–282.PubMed
100.
Olafsen T, Betting D, Kenanova VE, et al. Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas. J Nucl Med. 2009;50(9):1500–1508.PubMedPubMedCentralCrossRef
101.
Olafsen T, Sirk SJ, Betting DJ, et al. ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies). Protein Eng Des Sel. 2010;23(4):243–249.PubMedPubMedCentralCrossRef
102.
Paudyal P, Paudyal B, Iida Y, et al. Dual functional molecular imaging probe targeting CD20 with PET and optical imaging. Oncol Rep. 2009;22(1):115–119.PubMedCrossRef
103.
Mendler CT, Friedrich L, Laitinen I, et al. High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation. MAbs. 2015;7(1):96–109.PubMedCrossRef
104.
Younes A, Kadin ME. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol. 2003;21(18):3526–3534.PubMedCrossRef
105.
Durkop H, Foss HD, Eitelbach F, et al. Expression of the CD30 antigen in non-lymphoid tissues and cells. J Pathol. 2000;190(5):613–618.PubMedCrossRef
106.
Li P, Jiang L, Zhang X, Liu J, Wang H. CD30 expression is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. BMC Cancer. 2014;14:890.PubMedPubMedCentralCrossRef
107.
Sharman JP, Goldschmidt JH, Burke JM, Hellerstedt BA, McIntyre K, Yasenchak CA, et al. CD30 expression in nonlymphomatous malignancies. J Clin Oncol. 2012;30 Suppl, abstract 3069.
108.
Newland AM, Li JX, Wasco LE, Aziz MT, Lowe DK. Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate. Pharmacotherapy. 2013;33(1):93–104.PubMedCrossRef
109.
Nagai H. Recent advances in Hodgkin lymphoma: interim PET and molecular-targeted therapy. J Clin Oncol. 2015;45(2):137–145.
110.
Schirrmann T, Steinwand M, Wezler X, Ten Haaf A, Tur MK, Barth S. CD30 as a therapeutic target for lymphoma. BioDrugs. 2014;28(2):181–209.PubMedCrossRef
111.
112.
113.
Moss A, Gudas J, Albertson T, Whiting N, Law C-L. Abstract 104: Preclinical microPET/CT imaging of 89Zr-Df-SGN-35 in mice bearing xenografted CD30 expressing and non-expressing tumors. Cancer Res. 2014;74:104–109.CrossRef
114.
Rylova SN, Del Pozzo L, Klingeberg C, et al. Immuno-PET imaging of CD30-positive lymphoma using 89Zr-desferrioxamine-labeled CD30-specific AC-10 antibody. J Nucl Med. 2016;57(1):96–102.PubMedCrossRef
115.
Chamarthy MR, Williams SC, Moadel RM. Radioimmunotherapy of non-Hodgkin’s lymphoma: from the ‘magic bullets’ to ‘radioactive magic bullets’. Yale J Biol Med. 2011;84(4):391–407.PubMedPubMedCentral
116.
Iagaru A, Gambhir SS, Goris ML. 90Y-ibritumomab therapy in refractory non-Hodgkin's lymphoma: observations from 111In-ibritumomab pretreatment imaging. J Nucl Med. 2008;49(11):1809–1812.
117.
Perk LR, Visser OJ, Stigter-van Walsum M, et al. Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography. Eur J Nucl Med Mol Imaging. 2006;33(11):1337–1345.PubMedCrossRef
118.
Rizvi SN, Visser OJ, Vosjan MJ, et al. Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin’s lymphoma using 89Zr-ibritumomab tiuxetan and PET. Eur J Nucl Med Mol Imaging. 2012;39(3):512–520.PubMedPubMedCentralCrossRef
119.
Muylle K, Flamen P, Vugts DJ, et al. Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab. Eur J Nucl Med Mol Imaging. 2015;42(8):1304–1314.PubMedPubMedCentralCrossRef
120.
121.
DeNardo GL. Treatment of non-Hodgkin’s lymphoma (NHL) with radiolabeled antibodies (mAbs). Semin Nucl Med. 2005;35(3):202–211.PubMedCrossRef
122.
Davies AJ. Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab. Oncogene. 2007;26(25):3614–3628.PubMedCrossRef
123.
Press OW, Unger JM, Rimsza LM, et al. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol. 2013;31(3):314–320.PubMedCrossRef
124.
Jovanovic D, Djurdjevic P, Andjelkovic N, Zivic L. Possible role of CD22, CD79b and CD20 expression in distinguishing small lymphocytic lymphoma from chronic lymphocytic leukemia. Contemp Oncol (Pozn). 2014;18(1):29–33.
125.
Witzig TE, Tomblyn MB, Misleh JG, et al. Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma. Haematologica. 2014;99(11):1738–1745.PubMedPubMedCentralCrossRef
126.
Bodet-Milin C, Kraeber-Bodere F, Dupas B, et al. Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin’s lymphoma by 18F-fluorodeoxyglucose positron emission tomography. Haematologica. 2008;93(3):390–397.PubMedCrossRef
127.
DeNardo SJ, DeNardo GL, O’Grady LF, et al. Treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodies. Int J Biol Markers. 1987;2(1):49–53.PubMed
128.
DeNardo GL, DeNardo SJ, Goldstein DS, et al. Maximum-tolerated dose, toxicity, and efficacy of I-131-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin’s lymphoma. J Clin Oncol. 1998;16(10):3246–3256.PubMed
129.
Pagel JM, Pantelias A, Hedin N, et al. Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas. Cancer Res. 2007;67(12):5921–5928.PubMedCrossRef
130.
Czuczman MS, Straus DJ, Divgi CR, et al. Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin’s lymphoma. J Clin Oncol. 1993;11(10):2021–2029.PubMed
131.
Scheinberg DA, Straus DJ, Yeh SD, et al. A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin’s lymphoma: effects of tumor burden and antigen expression. J Clin Oncol. 1990;8(5):792–803.PubMed
132.
Press OW, Eary JF, Badger CC, et al. Treatment of refractory non-Hodgkin’s lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol. 1989;7(8):1027–1038.PubMed
133.
Kaminski MS, Fig LM, Zasadny KR, et al. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol. 1992;10(11):1696–1711.PubMed
134.
DeNardo GL, Natarajan A, Hok S, et al. Pharmacokinetic characterization in xenografted mice of a series of first-generation mimics for HLA-DR antibody, Lym-1, as carrier molecules to image and treat lymphoma. J Nucl Med. 2007;48(8):1338–1347.PubMedCrossRef
135.
Juweid ME. Radioimmunotherapy of B-cell non-Hodgkin’s lymphoma: from clinical trials to clinical practice. J Nucl Med. 2002;43(11):1507–1529.PubMed
136.
Reagan PM, Friedberg JW. Advancing radioimmunotherapy and its future role in non-Hodgkin lymphoma. Future Oncol. 2015;11(10):1543–1553.PubMedCrossRef
137.
138.
Attanoos R. Lymphoproliferative conditions of the serosa. Arch Pathol Lab Med. 2012;136(3):268–276.PubMedCrossRef
139.
Griffeth LK. Use of PET/CT scanning in cancer patients: technical and practical considerations. Proc (Bayl Univ Med Cent). 2005;18(4):321–330.
140.
Yang ZZ, Grote DM, Ziesmer SC, Xiu B, Novak AJ, Ansell SM. PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival. Blood Cancer J. 2015;5, e281.PubMedPubMedCentralCrossRef
141.
Xerri L, Devilard E, Hassoun J, Olive D, Birg F. In vivo expression of the CTLA4 inhibitory receptor in malignant and reactive cells from human lymphomas. J Pathol. 1997;183(2):182–187.PubMedCrossRef
142.
Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311–319.PubMedCrossRef
143.
144.
Ehlerding EB, England CG, McNeel DG, Cai W. Molecular imaging of immunotherapy targets in cancer. J Nucl Med. 2016;57(10):1487–1492.PubMedCrossRef
145.
Natarajan A, Hackel BJ, Gambhir SS. A novel engineered anti-CD20 tracer enables early time PET imaging in a humanized transgenic mouse model of B-cell non-Hodgkins lymphoma. Clin Cancer Res. 2013;19(24):6820–6829.PubMedCrossRef
146.
Tzankov A, Leu N, Muenst S, et al. Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study. J Hematol Oncol. 2015;8:70–77.PubMedPubMedCentralCrossRef
147.
Chuang WY, Chang H, Shih LY, et al. CD5 positivity is an independent adverse prognostic factor in elderly patients with diffuse large B cell lymphoma. Virchows Arch. 2015;467(5):571–582.PubMedCrossRef
148.
Khandani AH, Dunphy CH, Meteesatien P, Dufault DL, Ivanovic M, Shea TC. Glut1 and Glut3 expression in lymphoma and their association with tumor intensity on 18F-fluorodeoxyglucose positron emission tomography. Nucl Med Commun. 2009;30(8):594–601.PubMedCrossRef
149.
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2008.
Metadaten
Titel
Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies
verfasst von
Christopher G. England
Lixin Rui
Weibo Cai
Publikationsdatum
14.11.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 3/2017
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-016-3560-9

Weitere Artikel der Ausgabe 3/2017

European Journal of Nuclear Medicine and Molecular Imaging 3/2017 Zur Ausgabe

Editorial Commentary

“la synoviorthèse” can more than synovitis!

Original Article

Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer’s disease and elderly controls after oral administration of sembragiline

Original Article

Influence of blood-brain barrier permeability on O-(2-18F-fluoroethyl)-L-tyrosine uptake in rat gliomas

Editorial

The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis

Original Article

The clinical utility of FDG PET/CT among solid organ transplant recipients suspected of malignancy or infection

Original Article

Computed-tomography-guided anatomic standardization for quantitative assessment of dopamine transporter SPECT